Grant-Huerta Yanina's Form 4 filing
Atara Biotherapeutics, Inc.ATRA · filed May 20, 2025
- Accession no.
- 0000905148-25-001866
- Filed
- May 20, 2025
- Trade date
- May 16, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $15.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Grant-Huerta YaninaCIK 0002064348 | Officer (Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2025 | Common Stock | SSaleDisposed | −2,218 | $6.76F2 | −$14,993.68 | 37,067 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2025 and May 19, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Referenced by the price of 1 transaction in Table I.